Olive oil mill effluents as a feedstock for production of biodegradable polymers

The aim of the present paper was to study the feasibility of using olive oil mill effluents (OMEs) as a substrate in biodegradable polymer production. OMEs were anaerobically fermented to obtain volatile fatty acids (VFAs), which are the most highly used substrate for polyhydroxyalkanotes (PHAs) production. The anaerobic fermentation step was studied both without pretreatment and with different pretreatments (i.e., centrifugation, bentonite addition, and bentonite addition followed by centrifugation) and at various concentrations (28.5, 36.7 and 70.4 g CODL(-1)). During fermentation, VFA concentration was determined (7-16 g CODL(-1)) as well as the corresponding yield with respect to initial COD (22-44%). At all initial concentrations, centrifugation pretreatment (with or without previous addition of bentonite) significantly increased the final VFA concentration and yield, whereas the addition of bentonite alone had no influence. Moreover, centrifugation pretreatment led to a different acid distribution, which affected the hydroxyvalerate (HV) content within the obtained copolymer poly beta-(hydroxybutyrate-hydroxyvalerate) [P(HB-HV)]. OMEs were tested for PHA production by using a mixed culture from an aerobic SBR. Centrifuged OMEs, both with or without fermentation, were tested. PHAs were produced from both matrices, but with fermented OMEs PHA production was much higher, because of the higher VFA concentration. The initial specific rate of PHA production obtained with fermented OMEs was approximately 420 mg COD g COD(-1)h(-1) and the maximum HV content within the copolymer was about 11% (on a molar basis). The HV monomer was produced only until propionic acid remained present in the medium.

Removal of molecular weight fractions of COD and phenolic compounds in an integrated treatment of olive oil mill effluents

Previous works (Beccari et al. 1999b; Beccari et al. 2001a; Beccari et al. 2001b) on the anaerobic treatment of olive oil mill effluents (OME) have shown: (a) a pre-treatment based on the addition of Ca(OH)2 and bentonite was able to remove lipids (i.e. the most inhibiting substances present in OME) almost quantitatively; (b) the mixture OME-Ca(OH)2-bentonite, fed to a methanogenic reactor without providing an intermediate phase separation, gave way to high biogas production even at very low dilution ratios; (c) the effluent from the methanogenic reactor still contained significant concentrations of residual phenolic compounds (i.e. the most biorecalcitrant substances present in OME). Consequently, this paper was aimed at evaluating the fate of the phenolic fractions with different molecular weights during the sequence of operations (adsorption on bentonite, methanogenic digestion, activated sludge post-treatment). The results show that a very high percentage (above 80%) of the phenolic fraction below 500 D is removed by the methanogenic process whereas the phenolic fractions above 1,000 D are significantly adsorbed on bentonite; the 8-day activated sludge post-treatment allows an additional removal of about 40% of total filtered phenolic compounds. The complete sequence of treatments was able to remove more than the 96% of the phenolic fraction below 500 D (i.e. the most toxic fraction towards plant germination). Preliminary respirometric tests show low level of inhibition exerted by the effluent from the methanogenic reactor on aerobic activated sludges taken from full-scale municipal wastewater plants.

[Chronicity in psychiatry. Study of the course of mental disorders in relation to numerical variations in the nuclear family]

Research on the chronic patient in psychiatry is reviewed and a systemic interpretative protocol given so as to examine the role of family interaction factors implicated in the development of mental disturbance. Some research is then reported based on patients in a psychiatric ward in which the general features of the phenomenon are studied and an attempt made to assess the significance of the variable "numerical variations in the family nucleus" compared to the development of the psychopathological disturbance. The results show only a small influence of this variable on the long-term course of individual psychopathology.

Clinical activity and tolerability of trazodone, mianserin, and amitriptyline in elderly subjects with major depression: a controlled multicenter trial

The aim of this multicenter study was to compare trazodone (TRA) with two reference drugs, amitriptyline (AMI) and mianserin (MIA), under double-blind conditions, in an elderly population, to ascertain age-related patterns for efficacy and tolerability. One hundred six elderly depressed inpatients, ranging in age from 60 to 83 years, diagnosed as having major depression according to DSM-III, were treated with 75 mg AMI (37 patients), 60 mg MIA (33 patients) or 150 mg TRA (36 patients) p.o.t.i.d. for 5 weeks. There were no differences in the clinical outcome among the three groups of patients at the end of the trial, with a significant amelioration (p less than 0.01) for the Hamilton Rating Scale for Depression (HRS-D) and the Geriatric Depression Scale (GDS). TRA showed a lower overall prevalence of side effects than AMI or MIA, particularly for anticholinergic (p = 0.03 vs. AMI) and cardiovascular (p = 0.05 vs. MIA) effects. For these data GDS seems to be most reliable in detecting changes in elderly depressive symptomatology; moreover a comparable therapeutic response (among the three drugs) but a better tolerance for atypical antidepressants, particularly TRA, make advisable the use of the latter drug in the elderly population.

Trazodone in late life depressive states: a double-blind multicenter study versus amitriptyline and mianserin

Seventy five elderly depressed in-patients, ages ranging from 60 to 83 years, diagnosed as Major Depression according to DSM III were treated, under double-blind conditions, with 75 mg Amitriptyline (AMI) (26 patients), 60 mg Mianserin (MIA) (24 patients) or 150 mg Trazodone (TRZ) (25 patients) p.o. for 5 weeks. There were no differences in the clinical outcome between the three groups of patients at the end of the trial, with a significant amelioration (P less than 0.01) at the Hamilton Rating Scale for Depression and Geriatric Depression Scale. TRZ showed a significantly lower incidence of side effects compared to MIA and AMI. Atypical antidepressants, including TRZ, seem more suitable for treating elderly depression than the first generation antidepressants on the basis of risk/benefit ratio considerations.